NO20024921L - Kombinasjon av organiske forbindelser - Google Patents

Kombinasjon av organiske forbindelser

Info

Publication number
NO20024921L
NO20024921L NO20024921A NO20024921A NO20024921L NO 20024921 L NO20024921 L NO 20024921L NO 20024921 A NO20024921 A NO 20024921A NO 20024921 A NO20024921 A NO 20024921A NO 20024921 L NO20024921 L NO 20024921L
Authority
NO
Norway
Prior art keywords
combination
pharmaceutically acceptable
acceptable salt
organic compounds
receptor antagonist
Prior art date
Application number
NO20024921A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024921D0 (no
Inventor
Marc De Gasparo
Kurt Graves
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20024921D0 publication Critical patent/NO20024921D0/no
Publication of NO20024921L publication Critical patent/NO20024921L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024921A 2000-04-12 2002-10-11 Kombinasjon av organiske forbindelser NO20024921L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19674300P 2000-04-12 2000-04-12
PCT/EP2001/004115 WO2001076573A2 (en) 2000-04-12 2001-04-10 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups

Publications (2)

Publication Number Publication Date
NO20024921D0 NO20024921D0 (no) 2002-10-11
NO20024921L true NO20024921L (no) 2002-11-07

Family

ID=22726659

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024921A NO20024921L (no) 2000-04-12 2002-10-11 Kombinasjon av organiske forbindelser

Country Status (20)

Country Link
US (2) US20040023840A1 (de)
EP (1) EP1326604A2 (de)
JP (1) JP2003530342A (de)
KR (1) KR20020089433A (de)
CN (2) CN1440283A (de)
AR (1) AR032152A1 (de)
AU (1) AU2001258323A1 (de)
BR (1) BR0109966A (de)
CA (1) CA2405793A1 (de)
CZ (1) CZ20023381A3 (de)
HU (1) HUP0400475A3 (de)
IL (1) IL152079A0 (de)
MX (1) MXPA02010090A (de)
NO (1) NO20024921L (de)
PE (1) PE20020229A1 (de)
PL (1) PL365696A1 (de)
RU (1) RU2298418C2 (de)
SK (1) SK14642002A3 (de)
WO (1) WO2001076573A2 (de)
ZA (1) ZA200208203B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
EP1386608B1 (de) * 2001-04-19 2011-06-01 Kowa Co., Ltd. Mittel zur behandlung von glomerulopathie
WO2003035039A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
EP1450793A2 (de) * 2001-11-23 2004-09-01 Solvay Pharmaceuticals GmbH Hypertoniebehandlung während der akuten phase des schlaganfalls
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE551056T1 (de) 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP1818056A1 (de) * 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
WO2004096278A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited アディポネクチン産生増強剤
EP1618893A4 (de) 2003-04-28 2009-08-12 Sankyo Co Mittel zur verstärkung der zuckeraufnahmefähigkeit
EP1644375A2 (de) 2003-07-14 2006-04-12 Arena Pharmaceuticals, Inc. Kondensierte aryl- und heteroarylderivate als stoffwechselmodulatoren und die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
KR20060124634A (ko) * 2003-12-16 2006-12-05 노파르티스 아게 유기 화합물의 용도
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
US8022086B2 (en) 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
KR101436644B1 (ko) * 2006-01-31 2014-09-01 코와 가부시키가이샤 당뇨병 치료제
US8685952B2 (en) 2006-01-31 2014-04-01 Kowa Co., Ltd. Method for the treatment of diabetes
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
EP3323818A1 (de) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
RU2505297C1 (ru) * 2012-11-21 2014-01-27 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Средство для медикаментозной коррекции нарушений нитроксидергической системы
US9731864B2 (en) * 2013-05-13 2017-08-15 Macro Plastics, Inc. Shipping container and safety catch therefor
BR102013028883A2 (pt) * 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
EP3242666B1 (de) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Wirkstoff zur behandlung von mit s1p1-rezeptor zusammenhängenden erkrankungen
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EA034975B1 (ru) * 2018-03-13 2020-04-13 Владимир Александрович Горшков-Кантакузен Способ лечения лабильной и пароксизмальной гипертензии

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
JPH11503139A (ja) * 1995-04-07 1999-03-23 ノバルティス・アクチエンゲゼルシャフト ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
ES2198564T3 (es) * 1996-03-29 2004-02-01 Smithkline Beecham Corporation Dihidrato de eprosartan y un procedimiento para su produccion y formulacion.
DE69734405T2 (de) * 1996-07-15 2006-08-03 Sankyo Co., Ltd. Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose

Also Published As

Publication number Publication date
WO2001076573A2 (en) 2001-10-18
CZ20023381A3 (cs) 2003-02-12
MXPA02010090A (es) 2003-02-12
JP2003530342A (ja) 2003-10-14
US20040023840A1 (en) 2004-02-05
SK14642002A3 (sk) 2003-05-02
BR0109966A (pt) 2003-08-05
EP1326604A2 (de) 2003-07-16
RU2298418C2 (ru) 2007-05-10
PL365696A1 (en) 2005-01-10
NO20024921D0 (no) 2002-10-11
WO2001076573A3 (en) 2003-04-17
ZA200208203B (en) 2003-11-07
AR032152A1 (es) 2003-10-29
CN1651087A (zh) 2005-08-10
KR20020089433A (ko) 2002-11-29
CA2405793A1 (en) 2001-10-18
HUP0400475A3 (en) 2006-02-28
US20070105894A1 (en) 2007-05-10
IL152079A0 (en) 2003-05-29
HUP0400475A2 (hu) 2004-06-28
AU2001258323A1 (en) 2001-10-23
CN1440283A (zh) 2003-09-03
PE20020229A1 (es) 2002-04-11

Similar Documents

Publication Publication Date Title
NO20024921L (no) Kombinasjon av organiske forbindelser
BR0110079A (pt) Combinação de compostos orgânicos
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
DK1216038T3 (da) Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
NZ593012A (en) Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
JO2503B1 (en) Benzathiazole derivatives
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
ME01335B (me) Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura
WO2003047514A3 (en) Reducing myelin-mediated inhibition of axon regeneration
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
NO20001515L (no) Vitronektin reseptor-antagonist
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
NO20013459D0 (no) Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
HUP0301257A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és topoizomeráz I és II inhibitorokat tartalmazó kombinált tumorellenes kompozíciók
MXPA03004023A (es) Compuestos quimicos.
ATE234308T1 (de) 3'-epi k-252a derivate
MXPA02006146A (es) Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application